Pregled bibliografske jedinice broj: 271320
Benefit from Beta Interferon in the Treatment of Multiple Sclerosis
Benefit from Beta Interferon in the Treatment of Multiple Sclerosis // Acta Clinica Croatica, 45 (2006), 1; 37-40 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 271320 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Benefit from Beta Interferon in the Treatment of Multiple Sclerosis
Autori
Bošnjak-Pašić, Marija ; Lisak, Marijana ; Uremović, Melita ; Vidrih, Branka, Demarin, Vida
Izvornik
Acta Clinica Croatica (0353-9466) 45
(2006), 1;
37-40
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Interferons - therapeutic use; Multiple sclerosis - drug therapy; Interferons - adverse effects; Treatment outcome; Clinical trials
(Multiple sclerosis - drug therapy; Interferons - adverse effects; Treatment outcome; Clinical trials)
Sažetak
Over the past twelve years, beta interferons la and lb have been inereasingly used as immunomodulatory agents in the treatment of multiple sclerosis as well as for prophylaxis of disease progression. In Croatia, the cost of beta interferons 1a and lb has been covered by the Croatian Institute of Health Insurance since 1997. Despite numerous doubts about their real benefit, having in mind their price, side effects and occurrence of neutralizing antibodies, numerous clinical trials have confirmed their efficacy The most efficient arc interferon beta la (Rebif© in a dose of 12 MIU, subcutaneously, three times per week), interferon beta 16 (Betaferon® in a dose of 8 MIU, subcutaneously, every other day) and interferon beta-la (Avonex® in a dose of 6 MIU weekly intramuscularly).
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus
Uključenost u ostale bibliografske baze podataka::
- Biological Abstracts
- Excerpta Medica
